Sandra Poole
CIK 1619622 · Chief Operating Officer · last filed 2026-05-21
Sandra Poole is a Chief Operating Officer who has filed 13 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for TVTX, was dated May 21, 2026. Current disclosed insider exposure totals $1.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.77M
4
13
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Director | 34,000 | $52.04 | $1.77M | $0 | 6 | 2026-05-21 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 6,500 | — | — | $0 | 2 | 2020-05-19 |
| LOGC | Chief Operating Officer | — | $7.06 | — | $0 | 2 | 2018-10-24 |
| ImmunoGen, Inc. (IMGN) Delisted | Executive VP, Tech Operations | — | $31.23 | — | $0 | 3 | 2016-10-20 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-21 | TVTX | Grant (A) | +4,000 | $0 | EDGAR |
| 2025-05-16 | TVTX | Grant (A) | +6,500 | $0 | EDGAR |
| 2024-05-10 | TVTX | Grant (A) | +6,500 | $0 | EDGAR |
| 2023-05-19 | TVTX | Grant (A) | +4,500 | $0 | EDGAR |
| 2022-05-12 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2021-05-18 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2020-05-19 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +3,000 | $0 | EDGAR |
| 2019-05-15 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +3,500 | $0 | EDGAR |
| 2018-10-24 | LOGC | Grant (A) | — | $0 | EDGAR |
| 2018-10-22 | LOGC | Grant (A) | — | $0 | EDGAR |